Payload · Auristatin

Cys-mcMMAF

Tubulin inhibitor

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC

Physicochemistry

Properties

1046.3 Da

XLogP3

1.4

logD₇.₄

-1

TPSA

301 Å²

pKa

3.5

Charge pH 7.4

-1

H-bond donors

H-bond acceptors

Bystander

PubChem CID

10395173

Bioactivity

ADCdb (DRG0NDXRU) reports a cell-based EC50 of 30.6 ug/mL on EL4 cells (moderate BCMA expression) and Phase 1 clinical efficacy (ORR 60% at 3.4 mg/kg; median PFS 12 months; median DoR 14.3 months). MMAF is an antimitotic tubulin-polymerization inhibitor.

11 agents